AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22303699
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride sustained release tablets administered at 12h, 24h, 48h postoperation and before cleaning up procession
Trial: 22303699
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no administration of Tramadol)
Trial: 16684263
Drug: Iron plus
RxNorm normalized name: Nu-Iron Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron plus triple therapy for H. pylori
Trial: 16054522
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition supplemented with dipeptide alanyl‐glutamine
Trial: 16054522
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (standard)
Trial: 7554318
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine oestrogen (1.25 mg daily)
Trial: 7554318
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐oestradiol (100 micrograms daily)
Trial: 7554318
Drug: Both oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oestrogen treatments
Trial: 7554318
Drug: Neither oral
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither oral nor transdermal oestrogen
Trial: 2298404
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) treatment arm (60 mg/m2 starting dose, maximum cumulative dose of 500 mg/m2)
Trial: 7436691
Drug: Tryptophan (L‐tryptophan)
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan (L‐tryptophan)
Trial: 22072307
Drug: Combination docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination docetaxel and carboplatin (cDC): weekly docetaxel 30 mg/m² on days 1 and 8 and carboplatin AUC = 6 on day 1, every 3 weeks
Trial: 22072307
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with docetaxel then carboplatin (sDC): docetaxel 30 mg/m² on days 1 and 8 for 6 cycles followed by carboplatin AUC = 6 on day 1 for 6 cycles
Trial: 20541024
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids plus a second immunosuppressive agent
Trial: 17255748
Drug: Remune, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remune, an inactivated HIV‐1 vaccine
Trial: 15821223
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - continuous infusion starting with 50 mg/kg/4 h followed by 100 mg/kg/24 h for 44 h (n = 18)
Trial: 8762660
Drug: Dobesilate of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobesilate of calcium with dexamethasone acetate and lidocaine (Treatment A)
Trial: 8762660
Drug: Prednisolone capronate
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone capronate with dibucaine hydrochloride (Treatment B)
Trial: 2496791
Drug: Omeprazole 30
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 30 mg daily for six weeks
Trial: 348251
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for six weeks
Trial: 30073267
Drug: Cochlear Implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear Implants (CIs)
Trial: 28613971
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy Self-Help Booklet (CBT-SHB) with usual care
Trial: 19714630
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) alone (> or =10 mg/m(2)/week, maximum dosage 1 mg/kg/week)
Trial: 19714630
Drug: Etanercept alone
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept alone (0.8 mg/kg/week, maximum dose 50 mg)
Trial: 19714630
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (MTX, etanercept, etanercept plus MTX)
Trial: 17533209
Drug: TLC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC diet plus soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Trial: 15232517
Drug: IT 2.5
RxNorm normalized name: Procto-Kit 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT 2.5 mg levobupivacaine + 25 microg fentanyl (LF)
Trial: 15232517
Drug: IT 2.5
RxNorm normalized name: Procto-Kit 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT 2.5 mg levobupivacaine (L)
Trial: 10079864
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (specific antibiotics not detailed)
Trial: 10079864
Drug: Immunotherapy (immunocorrection)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (immunocorrection)
Trial: 10079864
Drug: Various physiochemical
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various physiochemical methods in complex treatment
Trial: 2610720
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release Capsule (Elantan), 50 mg
Trial: 2610720
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release Tablet, 50 mg
Trial: 2610720
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release Capsule, 100 mg
Trial: 2610720
Drug: Non Sustained
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non Sustained Release Tablets, 40 mg
Trial: 2610720
Drug: Non Sustained
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non Sustained Release Tablets, 2 x 20 mg
Trial: 31445343
Drug: Quetiapine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine plus adjunctive personalized therapy
Trial: 29088099
Drug: Anserine/carnosine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anserine/carnosine supplementation (ACS) 1.0 g (3:1) for 3 months
Trial: 16145319
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone therapy (0.05 mg 17[beta]-estradiol every 24 hours combined with 5 mg oral dydrogesterone daily)
Trial: 16145319
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone therapy (2 mg 17[beta]-estradiol semihydrate every 24 hours combined with 10 mg dydrogesterone)
Trial: 16145319
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone therapy
Trial: 16145319
Drug: Oral hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormone therapy
Trial: 16145319
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (both routes)
Trial: 681999
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5000 units)
Trial: 28631179
Drug: Volasertib in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib in combination with cytarabine
Trial: 28631179
Drug: Cytarabine in
RxNorm normalized name: cytarabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine in combination with volasertib
Trial: 25035291
Drug: Lomustine 110
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lomustine 110 mg/m² once every 6 weeks
Trial: 25035291
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg once every 2 weeks
Trial: 25035291
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg every 2 weeks and lomustine 90 mg/m² every 6 weeks
Trial: 25035291
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg every 2 weeks and lomustine 110 mg/m² every 6 weeks
Trial: 25035291
Drug: Bevacizumab and
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab and lomustine 90 mg/m²
Trial: 18752692
Drug: Food-based intervention
RxNorm normalized name: food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-based intervention consisting of six food items with modified cation content and 500 ml of maas (fermented milk)/d for 8 weeks
Trial: 18752692
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet providing the same quantities of targeted foods but of standard commercial composition and 500 ml/d of artificially sweetened cooldrink
Trial: 11137328
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol (1 mg) combined with Chlormadinone Acetate 5 mg
Trial: 11137328
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol 50 microg/24 h with Norethisterone Acetate (11.2 or 22.4 mg)
Trial: 9186533
Drug: Conventional induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional induction treatment with daunorubicin and cytarabine
Trial: 8244812
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy (daily 150-180 cGy fractions to 45-55 Gy in 5-6 weeks)
Trial: 3104051
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid preparation 1
Trial: 3104051
Drug: Liquid antacid
RxNorm normalized name: GNP Liquid Antacid Maximum Strength 400mg-400mg-40mg/5ml Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid antacid preparation 2
Trial: 29358194
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment with higher HDL cholesterol levels at month 3
Trial: 26888227
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg for the first dose and then 200 mg)
Trial: 26888227
Drug: Loxoprofen (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen (60 mg)
Trial: 26888227
Drug: Acetaminophen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (600 mg)
Trial: 24378207
Drug: DP-R206 (150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP-R206 (150-mg ibandronate/24,000-IU vitamin D3 tablet)
Trial: 24378207
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 24,000-IU tablet (reference drug)
Trial: 18794697
Drug: Rectal trumpet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal trumpet
Trial: 16094218
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (high potency)
Trial: 16094218
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (any varicella potency)
Trial: 16094218
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (1 or 2 injections)
Trial: 16094218
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (second injection)
Trial: 16094218
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of M-M-RII and VARIVAX
Trial: 12571431
Drug: Nefazodone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone monotherapy
Trial: 12571431
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with amitriptyline and haloperidol
Trial: 10561963
Drug: Terbinafine cream
RxNorm normalized name: terbinafine Topical Cream
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbinafine cream for 1 week
Trial: 10561963
Drug: Miconazole cream
RxNorm normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole cream for 4 weeks
Trial: 8678082
Drug: TMP-SMX 160/800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP-SMX 160/800 mg orally every 12 hours for 2 months
Trial: 1773691
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Verapamil and Enalapril
Trial: 27418270
Drug: Adjuvant girentuximab
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant girentuximab treatment
Trial: 16710287
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of irbesartan (ARB) and ramipril (ACE inhibitor)
Trial: 16710287
Drug: Ramipril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (ACE inhibitor) alone
Trial: 15587588
Drug: Tyrothricin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrothricin (0.1 g tyrothricin per 100 g of vehicle) applied twice daily for 9 days
Trial: 15587588
Drug: Placebo powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder applied twice daily for 9 days
Trial: 9215784
Drug: Temporary 125I
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary 125I implants with a median reference dose of 60 Gy
Trial: 9215784
Drug: Permanent 125I
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent 125I implants with a median reference dose of 100 Gy
Trial: 9215784
Drug: Temporary implants
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary implants
Trial: 9215784
Drug: 200 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 Gy isodose volume <4.5 ml
Trial: 9215784
Drug: 200 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 Gy isodose volume >4.5 ml
Trial: 8485323
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (PN) with high lipid content
Trial: 3609119
Drug: 5-FU 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 7.5 mg/kg
Trial: 3609119
Drug: 5-FU 15
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 15 mg/kg
Trial: 3609119
Drug: 5-FU 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 7.5 mg/kg and 15 mg/kg
Trial: 29080044
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice a day for 3 months
Trial: 29080044
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 3 months
Trial: 20621334
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups aggregated
Trial: 18676087
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg micronized progesterone for 21 days
Trial: 16361638
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 150 U/kg subcutaneously 3 times weekly until 3 weeks after completion of chemotherapy
Trial: 8160250
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine dihydrochloride 5 mg
Trial: 8160250
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine dihydrochloride 10 mg
Trial: 8160250
Drug: Oral fluphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluphenazine dihydrochloride 20 mg
Trial: 3292710
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 40 mg orally four times daily
Trial: 3292710
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg orally twice a day
Trial: 8049998
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy or chemoradiotherapy
Trial: 26675768
Drug: Yellow cassava
RxNorm normalized name: yellow OB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow cassava (mean content: 1460 μg β‐carotene/d)
Trial: 26675768
Drug: β‐carotene supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐carotene supplement (1053 μg/d)
Trial: 26675768
Drug: White cassava
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White cassava and placebo supplement (control group)
Trial: 24813595
Drug: Cinnamon supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon supplements (1.5 g/d)
Trial: 18812344
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg x kg(‐1) morphine sulfate interpleurally for 24 hours
Trial: 16047469
Drug: Ciprofloxacin, 500
RxNorm normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg bd for 12 weeks (n = 6)
Trial: 12496063
Drug: 160 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/day of red clover-derived dietary isoflavones
Trial: 7480524
Drug: ECTx3 (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECTx3 (three times weekly electroconvulsive therapy)
Trial: 2126420
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g MCT/LCT fats twice weekly
Trial: 2126420
Drug: 0.7 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g/kg body weight per day MCT/LCT fats
Trial: 2126420
Drug: 1.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/kg body weight per day MCT/LCT fats
Trial: 760752
Drug: BW501 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW501 100 mg
Trial: 760752
Drug: BW501 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW501 10 mg
Trial: 760752
Drug: BW501 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BW501 2 mg
Trial: 30449171
Drug: Personalized diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized diet (1.2‐1.5 g/kg of protein, 30% of energy from fat, 55‐60% of energy from carbohydrate), face to face nutrition education, pamphlet with nutrition information
Trial: 28586607
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for 5 days
Trial: 28586607
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment for 5 days
Trial: 20673892
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human chorionic gonadotropin (hCG)
Trial: 17404369
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (2 cycles of carboplatin AUC 6 and paclitaxel 200 mg/m2 every 21 days) followed by concurrent chemoradiotherapy (66 Gy of chest radiotherapy with carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly)